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Abstract
Background: Self-management programmes (SMP) are recommended for patients with fibromyalgia. The purpose
of this study was to evaluate effects of a one week multidisciplinary inpatient self-management programme on
psychological distress, skills as a consumer of health services, self-efficacy, and functional and symptomatic
consequences of fibromyalgia (FM).
Methods: A randomised controlled two-armed, assessor-blinded trial with three-week follow-up to evaluate SMP.
Primary outcomes were the General Health Questionnaire (GHQ-20) and the Effective Musculoskeletal Consumer
Scale (EC-17), while secondary outcomes included the Fibromyalgia Impact Questionnaire (FIQ) and Self-efficacy
scales for pain, function and symptoms (ASES).
Results: 150 patients with FM were randomised to one week one SMP (n = 75) or to a waiting list control group
(n = 75). Of these, 58 participants in the treatment group and 60 in the control group completed the study. At three
weeks’ follow up there was a significant difference in EC-17 (0-100) in favour of the treatment group (mean
difference 4.26, 95 CI 0.8 to 7.7, p = 0.02). There were no differences between the groups for any of the other
outcomes.
Conclusion: This study shows that in patients with FM the SMP had no effect on psychological distress, functional
and symptomatic consequences and self-efficacy, except for a small short-term effect on skills and behaviour that
are important for managing and participating in health care (EC-17). Clinical Trials.gov Id: NCT01035125.
Trial registration: Clinical Trials.gov Id: NCT01035125
Keywords: Self-management programme, RCT, Fibromyalgia
Background
Fibromyalgia syndrome (FM) is a common rheumatic
disease, with a prevalence of 3.2 in Norway. FM is char-
acterised by chronic pain, tender points, stiffness, fa-
tigue, depression, anxiety and sleep disturbance. FM also
includes other symptoms such as headaches, migraine,
abdominal pain and increased urinary frequency [1].
One review revealed that people with FM had a greater
disease burden compared to people with other specific
pain conditions [2].
People with FM experience a negative social response
to their disease [3]. They also perceive a lack of support
and acknowledgment which makes it difficult to move
on in living with an invisible illness [4]. In a study
among Norwegian physicians and medical students FM
scored lowest on disease prestige [5]. This may affect
prioritisation in medical practice.
The European League Against Rheumatism (EULAR) has
developed evidence-based recommendations for manage-
ment of FM. The recommendations are both pharmaco-
logical and non-pharmacological [6]. Non-pharmacological
recommendations include multidisciplinary approaches,
such as self-management programmes (SMP) [7-9] and
cognitive behaviour therapy (CBT) [10]. Barlow defines
self-management as the individual’s ability to manage the
symptoms, treatment, physical and psychosocial conse-
quences and life style changes inherent in living with a
* Correspondence: bente.hamnes@revmatismesykehuset.no
1Hospital for Rheumatic Diseases, Lillehammer, Norway
Full list of author information is available at the end of the article
© 2012 Hamnes et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Hamnes et al. BMC Musculoskeletal Disorders 2012, 13:189
http://www.biomedcentral.com/1471-2474/13/189
chronic condition [11]. SMPs have been developed to assist
people with chronic rheumatic diseases such as FM in their
efforts to cope with their disease in daily life. A review of
FM studies shows that SMP with or without exercise gave
no sustained benefits across a range of outcomes for more
than 6 months after completion of the SMP [12].
Studies also show that the same coping intervention
can vary in efficacy in patients with FM, from no im-
provement to significant pain reduction, increased pain-
coping abilities and reduction in healthcare consump-
tions one year after completed intervention [13,14].
A qualitative study of patients’ expectations prior to a
one week inpatient SMP revealed that they expected the
SMP to be a turning point to a better future and to em-
power them so that they could assume more responsibil-
ity for their own health and self-care. They also expected
the SMP to facilitate acceptance, help them gain new
knowledge and to be a forum in which to share their
experiences. Participants who were employed assumed
that participation in the SMP could help to ensure that
they would continue in their jobs [15].
A one-week inpatient SMP has been part of the rheuma-
tology service at the Hospital for Rheumatic Diseases in
Lillehammer for several years; therefore it was desirable to
study whether it had any effects. The objective in this ran-
domized controlled study was to evaluate the effect of a
one week inpatient SMP on psychological distress, coping
skills and behaviours, self-efficacy, and functional and
symptomatic consequences in patients with FM.
Methods
Design
This was a single centre, randomised, controlled two-
armed study which evaluated a one week inpatient SMP
for patients with FM. The participants were allocated to
the one week SMP or a waiting list control group. Parti-
cipants were included at Lillehammer Hospital for
Rheumatic Diseases from November 2008 to January
2010. Originally, the study was planned with follow up
after three weeks and six months. However, due to an
error in the study procedures, the control patients were
invited to participate in the SMP before they had com-
pleted the 6-months questionnaires. Thus the 6-months
follow-up data could not be collected.
Participants
Participants were patients with FM referred for a one
week SMP at Lillehammer Hospital for Rheumatic
Diseases. Inclusion criteria were diagnosis of FM accord-
ing to the American College of Rheumatology's criteria
[16], a desire to participate in the SMP, an ability to speak
the Norwegian language, age between 20 and 70 years,
and willingness to give written informed consent. Exclu-
sion criteria were previous participation in an SMP,
cognitive impairment, vision or hearing problems, and
serious mental disorders. The study was approved by the
Regional Committee for Medical Research Ethics and the
Norwegian Data Inspectorate.
Participants were assessed at inclusion before random-
isation (baseline 1), three weeks before the SMP (base-
line 2) and three weeks after the SMP. The time from
study inclusion to participation in the SMP varied from
one to six months. This was due to summer closure of
the patient education unit, and postponed participation
by some participants. This is the reason for the use of
both baseline 1 and 2.
Intervention
The one week inpatient SMP is a complex multidiscip-
linary self-management intervention [17]. The SMP has
been developed on the basis of Hiim and Hippe's didac-
tic relations model. This model contains six interrelated
concepts which are central in patient education: The
participant's learning abilities, pedagogical framework(s),
teaching goals, contents, learning/teaching methods and
evaluation. The model is developed to help teachers ana-
lyse, improve and evaluate didactic relations in practice
[18,19]. The SMP programme is based on a cognitive-
behavioural approach and focuses on enhancing self-
efficacy and coping with the disease and daily life [20].
Self-efficacy is the belief that one will be able to perform
a specific behaviour or task in the future [21]. Coping
with the stress of illness involves managing the stressors
(such as pain) stemming from the chronic illness [22].
The SMP also has an empowering approach aimed at
enhancing participants' knowledge, attitudes, skills and
behaviours and enabling them to take responsibility for
their own health management and daily life [21,23-25].
The programme is described in Table 1. The inpatient
education unit takes up to 16 patients and five spouses/
relatives/partners per week within the same diagnostic
group. Participants receive individual consultations with
the multidisciplinary team if needed.
Before participants submitted an application for the
programme, they received a brochure describing the
purpose of the stay, the main topics and the teaching
methods. Normal waiting time for participation in the
SMP is more than a year. Participants are referred from
all over the country, but the majority come from the two
nearest counties. A one week SMP makes it possible for
people who do not live close by to participate. All parti-
cipants in the study waited a shorter time to participate
in SMP than normal. The intervention group waited one
to six months and the control group eight months or
more from inclusion in the study until they participated
in the SMP. The waiting list control group did not re-
ceive any treatment at the hospital in the period from
inclusion to participation in the SMP.
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Table 1 The Self-Management Programme
Day/Health
profession
Theme Goal/objectives Methods
Sunday evening Arrival
Nurse Welcome and
introduction
Preparation for the week. Individual welcome
Group introduction (1 hr)
Monday Living with
chronic disease
Nurse My expectations Individual and group
My diagnoses Clarify expectations. exercises, discussions
Living with chronic
disease
Awareness of the impact of the diagnoses. Teaching and discussion
Own goals Introduction to important issues such as learning
and normal reactions to a chronic disease.
Individual targeted focus.
Writing goals (2.5 hrs)
Physiotherapist Exercise in
swimming pool
Learning exercises. Group exercises (0.5 hr)
Rheumatologist,
Assistant doctor
Medical
consultation
Check of status. Individual consultation (0.5 hr)
Tuesday Stress
management
Awareness of what triggers stress in everyday life. Individual exercise, group discussion
Teaching about stressors and stress
reactions (1 hr)Nurse Understanding stress mechanisms.
Physiotherapist Exercising and
relaxing
Knowledge, exercises and relaxation. Teaching and exercises (1 hr)
Rheumatologist Disease and
treatment
Understanding mechanisms of the disease, what
helps, and research.
TeachingDiscussions (2 hrs)
Representatives
from patient
organizations
Evening Meeting Patient organizations as external resource. Presentation of the organizations
(1 hr)
Wednesday Self-management Awareness of own coping strategies, communication,
values, choices. Connection between thoughts,
feelings and bodily reactions.
Exercises Discussions Teaching
Guided imagery (2.5 hrs)
Nurse
Ass. Occup.
Therapist
Activity Tour - walking in the local area Walking (0.5)
Occupational
Therapist
My priorities in
daily life
Awareness of how to affect own health through
prioritization of daily activities and use of energy.
Teaching
Exercise
Discussion (1 hr)
Ass. occup.therapist My priorities in
daily life,- daily
activity
Staying focused on positive activities. Creative activity or visiting a
museum (1.25 hrs)
Thursday Health and social
welfare
Knowledge on health and social rights, work rights. Teaching
Social worker Discussions (2.5 hrs)
Ass. occup.therapist Nordic walking Trying new activities. Walking in groups (0.5 hr)
Occupational
therapist
Practical advice
for everyday life
Knowledge on ergonomics, regulation of activity, aids. Demonstration, testing and
discussions (1.25 hrs)
Friday Healthy eating Consciousness about own diet. Teaching
Dietician Knowledge on nutrition, digestion, nutritional supplements
and intolerance. Promotion of positive attitudes towards
healthy eating.
Discussions (2 hrs)
Nurse Evaluation and
end of the
program
Experiences from the SMP. Oral and written evaluation
Focus on individual goals and the way forward. Sharing experiences (0.5 hr)
Monday, Tuesday,
Thursday evening
Group session in
smaller groups
Articulating how to live with FM and how to find new
coping strategies.
Discussions lead by health- care
professionals (1 hr)
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Assessments
Primary outcomes
The General Health Questionnaire (GHQ-20) [26-29] is a
20-item instrument for measuring psychological distress
in chronic diseases. The items use a four-point Likert scale
ranging from “no distress at all” to “much more distress
than usual” and are summated to give a total score from 0
to 60 where 0 is the best possible score indicating no dis-
tress. A score of 24 or more is defined as pathological psy-
chological distress [30]. Evidence of reliability and validity
[28,30-32] and responsiveness in Norwegian patients [28]
has been demonstrated for this instrument.
The Effective Musculoskeletal Consumer Scale (EC-17)
was used to assess patient perception of skills and beha-
viours that are important for effectively managing, partici-
pating in or leading their health care [33].
EC-17 is a self-administered instrument with 17 items
covering five skill domains: 1) How to use health informa-
tion, 2) How to clarify priorities, 3) Communication with
others, 4) How to negotiate own role and take control and
5) How to decide and take action. The items are sum-
mated and converted to produce a score from 0 to 100
where 100 is the best possible score [33,34]. The instru-
ment has been translated and validated into Norwegian,
and the results of a principal component analysis support
the unidimensionality of the EC-17 [35].
Secondary outcomes
The Arthritis Self-Efficacy scale (ASES) has been devel-
oped to measure perceived self-efficacy in people with
arthritis, and captures how confident an individual feels
in managing symptoms such as pain, functional limita-
tions and emotional issues. It includes three subscales
for pain (5 items), functioning (9 items) and other symp-
toms (6 items). Each item is scored from 10 (very uncer-
tain) to 100 (very certain). Each subscale is scored
separately by taking the mean of the subscale items [36].
ASES has been used in studies of multidisciplinary self-
management interventions of patients with FM [8] and
measures different skills and attributes to those of the
EC-17 [34].
The questionnaire included the Fibromyalgia Impact
Questionnaire (FIQ) which was developed to measure the
health status and the components that are believed to be
most affected by FM [37]. FIQ is a self-administered ques-
tionnaire with 10 items, each of which scores 0 to 10. The
score for the first item is the mean value of 10 sub-items
about physical function. The second item is the number
of days “feeling good” and the third item is absence from
work. This question has the same modification as the vali-
dated Swedish version, where the question on absence
from work has been changed from days to percentage
[38]. The last seven items are visual analogue scales (VAS)
for job ability, pain, fatigue, morning tiredness, stiffness,
anxiety and depression. The final score is the total score
of the 10 items, from 0 to 100. The average FM patient
scores about 50 and the severely affected patient scores 70
or more [39].
The participants completed the first questionnaire
when they were included (Baseline 1), before randomisa-
tion. The second questionnaire was returned by the par-
ticipants three weeks before the programme (Baseline 2).
The follow-up questionnaire was completed three weeks
after the programme. All questionnaires were sent out
by mail. If the participants had difficulty with completing
the questionnaire, they could call the project leader.
Additional variables
Demographic variables included age, sex, marital status,
years of education, employment status and disease dur-
ation (time since diagnosis).
Sample size
Power calculation was performed on the basis of a GHQ-
20 included in a pilot study conducted at the hospital [35].
Based on data from 21 participants with mean 24.1 and
SD 11.5 we calculated that a sample size of 73 patients for
each group was required. This would detect a difference
of 6 points on a scale from 0 to 60 points, with a signifi-
cance level of 0.05 and a power of 80, and an expected 20
loss to follow-up.
Randomisation
Participants were approved for SMP by the Department’s
Nursing Director and were then sent invitation to par-
ticipate in the study. Participants who were included in
the study were given ID numbers consecutively from 1-
150 and received the first baseline questionnaire. After
Baseline 1 assessments, all included participants were
randomly allocated to either the treatment group or the
control group. Three participants withdrew or were lost
to follow-up after Baseline 1 assessments. An independ-
ent Director of Economy generated a randomised list,
using Excel. An independent non-medical research as-
sistant thereafter linked the ID number with the rando-
mised list number. The participants were informed
about group allocation after the randomization. The re-
searcher did not have access to any data before data col-
lection was completed.
Statistical methods
Frequency distribution, means and standard deviation
(SD) were calculated for the demographic data at base-
line for control and intervention groups. Demographic
data were compared using chi-square tests for categor-
ical variables and a t-test for continuous data.
A multivariate random effects model was applied to as-
sess the association between the effect of the intervention
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on the selected primary and secondary variables at three-
weeks follow up. In order to adjust for baseline values and
to avoid regression to the mean, the baseline scores were
included as a covariate. We calculated the ICC coefficient,
version 2.1, in the Fleiss terminology, using a two-way
mixed model approach [40].
In addition we adjusted for gender, education, marital
status and currently employed (Yes/No). Significant vari-
ables only were included in the final model. To examine
perturbation, we used Cook’s d and multivariate DfFits
statistics as well as Covtracve and Covratio statistics
[41]. All p-values equal to or below 0.05 (5) were consid-
ered significant. The treatment effect sizes (Cohen’s d)
were calculated as the adjusted between-group differ-
ence in scores divided by the pooled SD of the baseline
scores for each variable. The analysis was performed in
Statistical Analysis System version 9.1.3 [42].
Results
Characteristics of participants
Of the 230 patients on the waiting list for SMP who
were asked to participate in the study, 77 (71 women
and 6 men) did not return the questionnaire, (see flow
diagram in Figure 1). Of the 153 patients who agreed to
participate three were excluded because they had
attended another SMP at the hospital. Of the 150 parti-
cipants who were included in the study one withdrew
and two were lost to follow up. Of the remaining 147
participants, comprising, 75 in the intervention group
and 72 in the waiting list group, 118 completed the
three-week follow-up, 58 (77) in the intervention group
and 60 (80) in the control group.
Baseline 1 and 2 scores for the FIQ were about 60 in
both groups, and lay between the mean average (50) and
severely affected (70) by FM [39]. There were significant
Asked to participate = 230
Excluded = 3
Included = 150
Baseline I = 147
Volunteered= 153
Withdrawals = 1
Lost to follow up= 2
Withdrawls= 1
Lost to follow up= 5
Withdrawls = 1
Baseline II =  69 Baseline II =  66
One-week intervention = 68
Follow up at three weeks = 58 Follow up at three weeks = 60
Withdrawls = 9
Lost to follow up= 1
Intervention = 75
Randomised
Waiting list = 72
Withdrawls =  2
Lost to follow up = 4
Withdrawls = 5
Lost to follow up = 1
Figure 1 Flow diagram of the participants in the randomised trial.
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differences in gender between the two groups, with six
men (8) in the SMP group, and none in the control
group (p = 0.01). There were no differences in age, dis-
ease duration or other socio-demographic variables be-
tween the intervention and control group (Table 2).
There were no significant correlations between the
demographic variables and the total score for GHQ20,
EC-17, FIQ and SEAS.
There were no statistical differences between baseline
one and two in the intervention or waiting list group.
The intra-class correlation (ICC) between Baseline 1 and
2 for GHQ20, ASES, EC-17 and FIQ varied from 0.66 to
0.84. Presented results are based on baseline two (three
weeks before SMP) and post-test three weeks after SMP
(Table 3).
Primary outcomes
No statistical differences were seen in the GHQ-20 between
the groups (p=0.55), except for a small statistically signifi-
cant difference between the intervention and control group
in the total score of the EC-17 three weeks after SMP, with
a mean difference of 4.26 and SD 17.55 (p=0.02) and an ef-
fect size of 0.24.
Secondary outcomes
There were no significant differences in SEAS and FIQ
between the intervention and control group three weeks
after the SMP.
Discussion
In this randomised controlled study, the main results
showed no statistically significant differences between
the intervention group and the waiting list group three
weeks after completion of a one week SMP in psycho-
logical distress, functional and symptomatic conse-
quences of FM and self-efficacy. There was, however, a
small short-term beneficial effect on skills and beha-
viours which are important for effectively managing, par-
ticipating in and leading one’s own health care (EC-17).
In our study, the participants had a high level of distress
without achieving reduced level of distress three weeks
after intervention. A review of cognitive-behavioural ther-
apies and exercise programmes over 5-24 weeks for
patients with fibromyalgia, reveals that participants who
are characterized by high levels of distress seem to benefit
most from non-pharmacological interventions [43]. Thus,
the role of distress as a mediator of effect is warranted for
further investigation.
In a qualitative study exploring participants' expecta-
tions prior to participation in the SMP, participants sta-
ted that they expected the SMP to empower them to
take more responsibility for their own health and self-
care [15]. These expectations are in line with the learn-
ing objectives of the SMP, which are to enable partici-
pants to be responsible and manage disease and daily
life. The results in the present study, showing a small ef-
fect on coping skills and behaviours of an ‘effective con-
sumer’, may indicate that participants are more aware of
their own responsibility. This is important in a changing
healthcare system that expects patients to be more active
and responsible for managing their disease and health-
care [33].
Assessed on the basis of the didactic relations model
[18,19], the lack of effect on distress, self-efficacy and
functional consequences may have many explanations. It
may be due to factors relevant to the participants' learning
abilities such as age, education, motivation and the disease
and its consequences. As the participants applied to take
part in the SMP, it can, however, be assumed that they are
motivated. Lack of effect may also be due to the content
and contextual factors such as professionals' skills or the
organisation of the programme [18,19]. Also, a one week
programme may be too intensive or the content may not
be in accordance with participants' needs. In other studies
evaluating the effect of SMPs, the interventions are orga-
nised in shorter sessions over a longer period of time,
which position the participants in a process where
changes in knowledge, attitudes and behaviour can take
Table 2 Socio-demographic characteristics for patients
with FM
Characteristics SMP group No.
(%)
Control group No.
(%)
Sex
Male 6 (8)
Female 69 (92) 72 (100)
Age (years)
Mean (SD) 45.4 (9.4) 49.7 (4.0)
Marital status
Single 5 5
Cohabitant 11 17
Married 45 36
Divorced 13 13
Widow 1 1
Education ≤12 years 57 (76.0) 57 (79)
Employment status
Employed 21 (28.0) 21 (29.2)
Not working/retired 1 (1.3) 1 (1.4)
Sick leave 17 (22.7) 20 (27.8)
Disability pension 36 (48.0) 29 (40.3)
Student 1 (1.4)
Duration of disease (years) Mean
(SD)
7.03 (7.21) 6.13 (6.53)
Total 75 72
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place throughout the entire programme [8,44]. Teaching
methods such as imparting information, counselling, exer-
cises and exchange of experiences may contribute to the
lack of effect [18,19]. In the qualitative study participants
expected the SMP to facilitate acceptance, help them gain
new knowledge and to be a forum in which to share their
experiences. Participants who were employed assumed
that participation in the SMP could help to ensure that
they would continue in their jobs [15]. These are topics
that are not currently prominent in the programme except
the sharing of experiences. The didactic model also
includes the choice of evaluation instruments and the suit-
ability of the timing of the evaluation [18,19].
As far as we know, this is the first time the EC-17 is
used as an outcome measure in the evaluation of a self-
management intervention. The results confirm the find-
ings in our previous validation study that the instrument
can detect changes in the characteristics and skills ne-
cessary to be an active and participatory user of health
services shortly after the intervention [35].
The present study has several limitations. One is that
the participants were aware of their group allocation
when they answered the questionnaires before the SMP
(Baseline 2). However, there were no detectable differ-
ences within or between the groups at baseline 1 and 2,
indicating that this knowledge had little impact on the
completion of the questionnaires.
There are also limitations in the generalisability of the
effect of this programme to other patients with FM. As
the participants choose themselves to apply for partici-
pation in the SMP, they were also probably highly moti-
vated to learn about how to cope with their illness and
daily life.
Norway is a long and sparsely-populated country. Or-
ganizing the SMP as a one week intensive programme
therefore makes it easier for patients who do not live close
to the hospital to participate. Spending a whole week to-
gether can also give the participants more time for reflec-
tion, talks and discussions that can facilitate the learning
process. The one week SMP should therefore be tested in
a new study, which evaluates both the short term and long
term (12 months or more) effects [12]. Before conducting
a new study the programme should be reviewed on the
basis of the didactic relations model of Hiim and Hippe
[18,19], and additional topics described by participants in
the qualitative study should be included [15].
Table 3 Mean (95% CI) scores and treatment effect (differences between baseline and post-treatment, 3weeks after
intervention) *
SMP group Control group Treatment effect (95 CI) P value Effect size}
Primary outcomes:
Psychological distress (GHQ20) (0 - 60, 0 = no distress) 0.552
Baseline 27.0 (11.0-57.2) 26.4 (10.0-50.2)
Post-treatment 25.0 ( 6.0-49.1) 24.6 (10.0-57.2) 0.96 (-2.2 to 4.1) 0.10
Effective Musculoskeletal Consumer Scale (EC-17) (0 -100 , 0 = never, 100= always) 0.016
Baseline 57.5 (22.1-88.2) 54.3 (0.0-86.8)
Post-treatment 63.0 (36.8-97.1) 56.8 (1.5-100) 4.26 (0.8 to 7.7) 0.24
Secondary outcomes:
Self-efficacy pain (10 - 100, 100=high SE) 0.387
Baseline 50.6 (18.0-82.0) 51.4 (10.0-98.0)
Post-treatment 54.8 (16.0-94.0) 52.3 (10.0-82.0) -1.83 (-6.0 to 2.3) 0.12
Self-efficacy symptoms (10 - 100, 100=high SE) 0.189
Baseline 57.8 (20.0-93.3) 57.7 (11.7-86.7)
Post-treatment 61.4 (35.0-91.7) 57.9 (23.3-90.0) 2.63 (-1.3 to 6.6) 0.20
Self –efficacy function (10-100, 100=high SE) 0.556
Baseline 77.9 (22.2-100.0) 74.7 (18.9-100.0)
Post-treatment 77.9 (32.2-100.0) 72.8 (16.7-100.0) 1.02 (-2.4 to 4.4) 0.06
Fibromyalgia Impact Questionnaire (0-10, 0 = low impact) 0.265
Baseline 59.0 (16.1-89.6) 59.7 (23.9-92.5)
Post-treatment 55.9 (7.0-90.5) 61.0 (23.2-93.2) -2.76 (-7.7 to 2.1) 0.15
*Adjusted for gender, education, marital status and currently employed (Yes/No).
}Effect sizes were calculated between-group difference divided by the pooled SD of the baseline scores.
(<0.2 trivial; 0.2-0.49, small, 0.5-0.79, moderate, ≥80, large).
GHQ20, General Health Questionnaire, SMP, Self-management programme.
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Conclusions
This study shows that in patients with FM, the SMP had
no effect on psychological distress, functional and symp-
tomatic consequences and self-efficacy, except for a
small short-term effect on skills and behaviour that are
important for managing and participating in health care
(EC-17).
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